Mediators of hedgehog signaling pathways, compositions and uses related thereto
The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.
1. A compound of the formula (II):
wherein, as valence and stability permit,
X represents —N(R 8 )—;
Z represents —NH— or a direct bond;
Y represents —C(═O)—, —C(═S)— or SO 2 ;
A represents —NH—;
G represents a phenyl or pyridyl ring fused to the ring to which it is attached;
R 1 represents a substituted or unsubstituted benzene ring, cyclopentyl ring, cyclohexyl ring or heterocyclyl ring selected from substituted or unsubstituted thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, benzodioxane, benzodioxole, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane, thiolane, oxazole, piperidine, piperazine, morpholine, lactone, lactam, azetidinone, pyrrolidinone, sultam or sultone rings, wherein the optional substituents on the R 1 ring are selected from nitro, halogen, cyano, lower alkyl, acylamino, alkoxy or alkylamino groups or a cycloalkyl, heterocyclyl, aryl or heteroaryl ring fused to the benzene or heterocyclyl ring;
R 2 represents from 0-4 substituents on the ring to which it is attached, where the substituents are selected from halogen, lower alkyl, lower alkenyl, aryl, heteroaryl, carbonyl group, thiocarbonyl, ketone, aldehyde, amino, cyano, nitro, azido, sulfonyl, sulfoxido, sulfate, sulfonate, sulfamoyl, sulfonamido, phosphoryl, phosphonate, phosphinate, J-R 8 , J-OH, J-lower alkyl, J-lower alkenyl, J-R 8 , J-SH, J-NH 2 , protected forms of the above, or any two R 2 , when occurring more than once in a cyclic or polycyclic structure, taken together form a 4- to 8-membered cycloalkyl, aryl, or heteroaryl;
R 3 represents a substituent on the ring to which it is attached, the substituent being at a position on the ring which is para to where the X group is attached, and the substituent being selected from halogen, hydroxyl, alkoxy, amino, alkylamino, cyano, nitro, lower alkyl, and acyl,
R 8 , independently for each occurrence, represents H, lower alkyl or cycloalkyl; and
J represents, independently for each occurrence, a chain having from 0-8 units selected from CK 2 , NK, O, and S, wherein K represents, independently for each occurrence, H or lower alkyl;
provided that, when J is CK 2 , R 1 is not a cyclohexyl ring; and
provided that, when R 8 is H, Z is a direct bond and Y is —C(═O)—, R 1 is not a disubstituted pyridine ring;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein X—Y—Z includes an amide, urea, or sulfonamide.
3. The compound of claim 1 , wherein R 1 is optionally substituted with from 1-5 substituents.
4. The compound of claim 1 , wherein the substituents on R 1 are selected from nitro, halogen, cyano, lower alkyl, acylamino, alkoxy, or alkylamino groups, or a benzene, 2,5-dioxacyclohexyl or 2,4-dioxacyclopentyl ring fused to the benzene or heterocyclyl ring.
5. The compound of claim 1 , wherein R 2 represents from 1-4 substituents as defined.
6. The compound of claim 5 , wherein R 2 represents from 1-4 substituents selected from halogen, cyano, nitro, alkoxy, amino, acylamino, a cycloalkyl, heterocyclyl, aryl, or heteroaryl fused to G, and lower alkyl.
7. The compound of claim 1 , wherein R 1 represents a substituted or unsubstituted benzene ring, cyclopentyl ring, cyclohexyl ring, thiophene ring, furan ring, isobenzofuran ring, pyridine ring, benzodioxane ring, or benzodioxole ring.
8. The compound of claim 1 , wherein R 1 represents a substituted or unsubstituted benzene ring or pyridine ring.
9. The compound of claim 1 , which is a compound selected from the following:
or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising one or more compounds according to claim 1 formulated together with one or more pharmaceutically acceptable carriers and/or diluents.